The Ultimate MDX Test: Charts, Code & Paywalls

Testing the new Bioinfometrics Next.js 15 MDX Compiler architecture with Recharts integration, Syntax Highlighting, and Supabase Gating.

By Martin DAVILA3/1/2026

Welcome to the new era of the Bioinfometrics Engine. This post is written entirely in .mdx and compiled dynamically on the server using React Server Components.

1. Syntax Highlighting

Thanks to rehype-pretty-code, any code written in markdown automatically gets a beautiful theme (like GitHub Dark/Light) that adapts to your preference, with a working Copy button!

// An example of our shiny new InteractiveGraph
import { InteractiveGraph } from "@/components/blog/InteractiveGraph";
 
export default function App() {
  return (
    <InteractiveGraph
      data={fundingData}
      config={{
        type: "bar",
        xAxisKey: "year",
        yAxisKeys: [{ key: "agritech", name: "AgriTech" }]
      }}
    />
  )
}

2. Universal Embedded Recharts

We no longer have to build custom layouts for data. We can just drop React Components straight into the markdown!

Global Bioeconomy Investments

Sector breakdown over the last 3 years.

3. Premium Content Gating

What happens if we drop a <PremiumChart /> in here? Since this markdown file has premium: false (or if you are a subscriber), the chart will render fully unlocked.

Subscriber Only Analysis

This chart dynamically blurs based on Supabase Authentication state.

2020Total: $900M
2021Total: $1250M
2022Total: $1850M

Premium Content

Subscribe to see interactive chart

4. Typography & GFM

  • We fully support Tables, Italics, and automatic inline code snippets.
  • Quotes look elegant and inherit the Brand Serif font.

"The ability to seamlessly inject React interactive components into standard Markdown is the holy grail of modern technical publishing."

A Quick Table

SectorGrowth (YoY)Market Cap
AgriTech+45%$2.4B
BioEnergy+12%$1.1B
BioMaterials+85%$800M

And that's it! The ultimate rendering engine is officially complete.

Found this article helpful? Share it with your network!

Discussion (0)

Sign in to join the conversation and share your thoughts

No comments yet. Be the first to start the discussion!